Recombinant DNA Advisory Committee - 12/2-3/93 
Steven Kradjian, Vical, Inc. 
John Krauss, University of Michigan Medical Center 
James Logan, University of Alabama, Birmingham 
Donald Longenecker, Viagene, Inc. 
Stephen Lupton, Targeted Genetics Corporation 
Dan Maneval, Canji, Inc. 
Tony Marcel, TMC Development 
Keith March, Genetic Therapy, Inc. 
Steve Marcus, Genetic Therapy, Inc. 
Alan McClelland, Genetic Therapy, Inc. 
Gerard McGarrity, Genetic Therapy, Inc. 
Duncan McVey, GenVec, Inc. 
Bruce Merchant, Viagene, Inc. 
Andra Miller, Food and Drug Administration 
Karen Millison, Genetic Therapy, Inc. 
Gaye Morgenthaler, Murenove, Inc. 
Gary Nabel, University of Michigan 
Jeffrey Ostrove, Microbiological Associates, Inc. 
Joseph Palca, National Public Radio 
Hubert Pehamburger, University of Vienna 
Michael Pensiero, Genetic Therapy, Inc. 
Anne Petruska, The Blue Sheet 
Stephen Pijar, University of Maryland 
Paul Recer, Associated Press 
Thomas Reynolds, Targeted Genetics Corporation 
Rex Rhein, Biotechnology Newswatch 
Joseph Rokovich, Somatix, Inc. 
Alan Schreiber, Vical, Inc. 
Friedrich Schuening, Fred Hutchinson Cancer Research Center 
Richard Scotland, Genzyme Corporation 
G. Terry Sharrer, Smithsonian Institution 
Tomiko Shimada, Ambience Awareness International 
Juliette Singh, Baxter Health Care 
Alan Smith, Genzyme Corporation 
Robert Sobol, San Diego Cancer Research Institute 
Eric Sorscher, University of Alabama, Birmingham 
Judith St. George, Genzyme Corporation 
Marcus Stem, Copley News Service 
Nevin Summers, Ingenex, Inc. 
Jennifer Sutton, Association of American Medical Colleges 
Paul Tolstoshev, Genetic Therapy, Inc. 
Bruce Trapnell, Genetic Therapy, Inc. 
Cynthia Utley, GenVec, Inc. 
Christine VandePol, Rhone Poulenc Rorer, Inc. 
Samuel Wadsworth, Genzyme Corporation 
Trish Waitschies, MD Anderson Cancer Center 
[516] 
Recombinant DNA Research, Volume 18 
